Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LND101 + unspecified immune checkpoint inhibitor |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LND101 | LND-101|LND 101 | Microbiome 9 | LND101 is a microbiome therapy derived from healthy donors, which may enhance antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12). | |
| unspecified immune checkpoint inhibitor | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06623461 | Phase II | unspecified immune checkpoint inhibitor LND101 + unspecified immune checkpoint inhibitor | LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (Canbiome2) | Recruiting | CAN | 0 |